Specification
Description
Cefcanel daloxate, also known as KY-109, is a pro-drug to improve oral absorption of KY-087. The antimicrobial activities of KY-087 against clinically isolated Gram-positive organisms were superior to those of CEX and CCL. The antimicrobial activities of KY-087 against Gram-negative organisms, such as Enterobacter sp., Serratia, and Pseudomonas sp., were less active. KY-087 showed dose-related bactericidal activity against Staphylococcus aureus and Escherichia coli. The therapeutic efficacy of KY-109 against experimental intraperitoneal infections caused by Gram-positive and Gram-negative organisms in mice was comparable to that of CEX but inferior to that of CCL. In experimental granuloma pouch models in rats and kidney infection in rabbits, therapeutic efficacy of KY-109 was either comparable or superior to that of CEX and CCL.
Synonyms
Cefcanel daloxate hydrochloride; Cefcanel daloxate HCl; KY-109; KY109; KY 109
IUPAC Name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (6R,7R)-7-((R)-2-((L-alanyl)oxy)-2-phenylacetamido)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, hydrochloride
Canonical SMILES
O=C(C(N12)=C(CSC3=NN=C(C)S3)CS[C@]2([H])[C@H](NC([C@H](OC([C@H](C)N)=O)C4=CC=CC=C4)=O)C1=O)OCC5=C(C)OC(O5)=O.[H]Cl
InChI
InChI=1S/C27H27N5O9S3.ClH/c1-12(28)24(35)41-20(15-7-5-4-6-8-15)21(33)29-18-22(34)32-19(25(36)38-9-17-13(2)39-27(37)40-17)16(10-42-23(18)32)11-43-26-31-30-14(3)44-26;/h4-8,12,18,20,23H,9-11,28H2,1-3H3,(H,29,33);1H/t12-,18+,20+,23+;/m0./s1
InChI Key
HFVATKYQUGKLGL-PCQLZLFJSA-N
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Alternative CAS
97275-40-6 (free base); 41952-52-7; 92602-21-6 (HCl)
Biological Target
Cefcanel daloxate, also known as KY-109, is a pro-drug to improve oral absorption of KY-087.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 46.45; H, 4.04; Cl, 5.08; N, 10.03; O, 20.62; S, 13.78
HS Tariff Code
2934.99.9001
In Vitro Activity
KY-087, which is the active form of KY-109, had broad antimicrobial spectrum against Gram-positive and Gram-negative organisms, but showed low antimicrobial activity against Enterobacter sp., Serratia, and Pseudomonas sp. The antimicrobial activities of KY-087 against clinically isolated Gram-positive organisms were superior to those of CEX and CCL.
Reference: J Antibiot (Tokyo). 1988 Jul;41(7):949-58. https://pubmed.ncbi.nlm.nih.gov/3417567/
In Vivo Activity
The in vivo efficacy of this prodrug (cefcanel daloxate) in comparison with cefaclor was assessed in a localized thigh infection model in mice. Both drugs caused a reduction in viable count by approx. 90% for all test organisms, while in the untreated animals the number of bacteria increased 4 to 10 times within 6 hours after challenge.
Reference: Scand J Infect Dis Suppl. 1990;74:185-9. https://pubmed.ncbi.nlm.nih.gov/2097707/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).